

DT01 Rev. 1 PCT/PT 2-3 DEC 2004

Substitute for Form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

1

of

2

**Complete if Known**

Application Number

10/519388

Filing Date

First Named Inventor

Helmut SCHMIDHAMMER

Art Unit

Examiner Name

Attorney Docket Number

1739-10PUS

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind-Code <sup>2</sup> (if known)			
CA		US-4,272,540	6-9-81	Razdan et al.	_____
CA		US-4,390,699	6-28-83	Brossi et al.	_____
CA		US-4,912,114	3-27-90	L. Revesz	_____
CA		US-4,176,186	11-27-79	Goldberg et al.	_____
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>4</sup> Number <sup>4</sup> Kind-Code <sup>5</sup> (if known)				
CA		UK 1,300,419	12/20/72	W. R. Buckett et al.	_____	
CA		EP 0 250 796	1/7/88	E. I. Du Pont De Nemours and Co.	_____	
CA		DE 3412727 A1	10/17/85	A. Gleich	_____	
CA		EP 0 030 685 A2	6/24/81	R. K. Razdan et al.	_____	
CA		WO2004/005294 A2	1/15/04	H. Schmidhammer et al.	_____	

Examiner  
Signature

AWLAKH

Date  
Considered

4/25/06

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \*Applicant's unique citation designation number (optional). \*See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. \*Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). \*For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \*Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. \*Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form call 1-800-PTO-0100 (1-800-786-9100) and select option 2

PTO1 Rec'd PCT/PTT 23-DEC-2004

Substitute for Form 1449/PTO		Complete if known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use as many sheets as necessary)		Application Number	107519388
		Filing Date	
		First Named Inventor	Helmut SCHMIDHAMMER
		Art Unit	
		Examiner Name	
Sheet 2 of 2	Attorney Docket Number	1739-10PUS	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
CA		Chen-Yu Cheng, et al., "N-Cubylmethyl Substituted Morphinoids as Novel Narcotic Antagonists", <u>Bioorganic &amp; Medicinal Chemistry</u> , Vol. 4, No. 1, pp 73-80, 1996.	
CA		A. Coop, et al., "Delta Opioid Binding Selectivity of 3-Ether Analogs of Naltrindole", <u>Bioorganic &amp; Medicinal Chemistry Letters</u> , 9 (1999) 3435-3438.	
CA		J. Schütz, et al., "Synthesis and Biological Evaluation of 14-Alkoxymorphinans. 17. Highly $\delta$ Opioid Receptor Selective 14-Alkoxy-Substituted Indolo- and Benzofuromorphinans", <u>J. Med. Chem.</u> 2002, 45, 5378-5383.	
CA		H. Schmidhammer, et al., "Synthesis and Biological Evaluation of 14-Alkoxymorphinans. 1. Highly Potent Opioid Agonists in the Series of (-) - 14 Methoxy-N-methylmorphinan-6-ones", <u>J. Med. Chem.</u> , 1964, 27, 1575-1579.	
CA		P. Klein, et al., "O <sup>3</sup> -(2-Carbomethoxyallyl) Ethers of Opioid Ligands Derived from Oxymorphone, Naltrexone, Etorphine, Diprenorphine, Norbinaltorphimine, and Naltrindole. Unexpected O <sup>3</sup> -Dealkylation in the Opioid Radioligand Displacement Assay", <u>J. Med. Chem.</u> , 1992, 35, 4589-4594.	
CA		P.S. Portoghesi, et al., "Synthesis of Naltrexone-Derived $\delta$ -Opioid Antagonists. Role of Conformation of the $\delta$ Address Moiety", <u>J. Med. Chem.</u> , 1994, 37, 579-585.	
CA		C. W. Funke, et al., "A <sup>1</sup> H and <sup>13</sup> C Nuclear Magnetic Resonance Study of Three Quaternary Salts of Naloxone and Oxymorphone", <u>J. Chem. Soc. Perkin Trans. II</u> , 1986, Pages 735-738.	

Examiner Signature	ALLACH	Date Considered	4/25/06
--------------------	--------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \* Applicant's unique citation designation number (optional). \* See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. \* Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). \* For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \* Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. \* Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form call 1-800-PTO-0199 (1-800-776-0199) and select option 2